BackTable Tumor Board Ep. 50 Beyond the Beam: Integrating Radiopharmaceuticals into Modern Oncology Practice with Dr. Ryan Funk
Though relatively new, there is a rapidly growing interest in the field of therapeutic radiopharmaceuticals and their potential to play a significant role in cancer treatment. This episode of BackTable Tumor Board covers recent developments in radiopharmaceutical therapies with radiation oncologists Dr. Dustin Boothe and Dr. Ryan Funk, where they discuss efficacy, side effects, and better tolerability of modern radiopharmaceuticals compared to older ones.
---
This podcast is supported by:
Siemens Healthineers
---
SYNPOSIS
Dr. Boothe and Dr. Funk cover the roles of radiation oncologists in treating patients and collaborating with different specialists, the challenges in starting a radiopharmaceutical program, and the importance of having an authorized user and radioactive materials license. They also delve into the promising future of radiopharmaceuticals, emphasizing potential advancements such as personalized dosimetry, new indications, and combination therapies.
---
TIMESTAMPS
00:00 - Introduction
02:54 - Understanding Radiopharmaceutical Terminology
04:40 - The Evolution of Radiopharmaceuticals
07:07 - The Rise of Targeted Radiopharmaceutical Therapies
12:35 - Radiation Oncologists’ Role in Systemic Therapy
23:55 - Challenges and Strategies in Practice Development
30:33 - Starting Up a Radiopharmaceutical Practice: Challenges, Authorized Users & RAM Licensing
37:47 - Advancing Practices with Clinical Trials and Dosimetry
44:48 - Future of Radiopharmaceutical Therapy
52:39 - Final Thoughts
---
RESOURCES
Siemens Healthineers: ARIA CORE for Theranostics
https://cancercare.siemens-healthineers.com/products/software/digital-oncology/aria-core-for-theranostics
PREEMPT Trial (NRG-CC014)
https://clinicaltrials.gov/study/NCT06745024#collaborators-and-investigators
Community Theranostics
https://www.communitytheranostics.com/